AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $15.41 and last traded at $15.3060, with a volume of 64390 shares traded. The stock had previously closed at $14.79.
Analysts Set New Price Targets
Several research analysts recently weighed in on the stock. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. HC Wainwright raised their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group boosted their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $19.50.
Get Our Latest Research Report on ANGO
AngioDynamics Stock Performance
AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities research analysts predict that AngioDynamics, Inc. will post -0.27 earnings per share for the current year.
Insider Transactions at AngioDynamics
In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.00% of the stock is currently owned by insiders.
Institutional Investors Weigh In On AngioDynamics
Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its position in AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after purchasing an additional 22,658 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after acquiring an additional 34,054 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 9,098 shares during the last quarter. Rhumbline Advisers grew its position in AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after acquiring an additional 2,510 shares in the last quarter. Finally, American Century Companies Inc. grew its position in AngioDynamics by 15.8% in the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after acquiring an additional 13,217 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.
About AngioDynamics
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
Featured Stories
- Five stocks we like better than AngioDynamics
- Large Caps Across Planes, Tech and Oil Announce Over $10 Billion in Buybacks
- A Sweet Beat and a Wearables Rally Came With Reasons to Pause
- 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
